| Name | Title | Contact Details |
|---|
Glacial Rx™ is the first age spot removal treatment that uses patented cooling technology to freeze melanin at the source, soothing your skin while effectively removing those annoying age spots.
CSP Medical is a London, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Humanscale is the premier designer and manufacturer of sustainable, high-performance ergonomic products for the workplace. Our award-winning solutions improve the health, efficiency and quality of work life. Since its founding in 1983, Humanscale has held the belief that design based on functionality and ease of use results in honest and enduring forms. Humanscale`s simple, elegant solutions stand the test of time—both functionally and aesthetically—while consuming as little of the Earth`s limited resources as possible. Nearly every Humanscale product can contribute to the achievement of LEED-CI, -NC and -EB credits. In addition to manufacturing premier ergonomic work tools, Humanscale`s team of certified ergonomists is available to help organizations further improve worker comfort, reduce injuries, and boost productivity through ergonomic assessments, training, and program development. With headquarters in New York City, Humanscale`s showrooms, offices and manufacturing facilities are strategically located throughout North America, Europe, Asia and Australia, while a worldwide network of esteemed distributors enables Humanscale solutions to reach every corner of the globe.
New England Brace Company is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.